These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24997317)

  • 1. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms.
    D'Avolio A; Carcieri C; Cusato J; Simiele M; Calcagno A; Allegra S; Sciandra M; Trentini L; Di Perri G; Bonora S
    J Antimicrob Chemother; 2014 Nov; 69(11):3061-6. PubMed ID: 24997317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study.
    Fatiguso G; Allegra S; Calcagno A; Baietto L; Motta I; Favata F; Cusato J; Bonora S; Perri GD; D'Avolio A
    Int J Pharm; 2016 Jan; 497(1-2):287-92. PubMed ID: 26642947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells.
    D'Avolio A; Simiele M; Calcagno A; Siccardi M; Larovere G; Agati S; Baietto L; Cusato J; Tettoni M; Sciandra M; Trentini L; Di Perri G; Bonora S
    J Antimicrob Chemother; 2013 Apr; 68(4):907-10. PubMed ID: 23221630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).
    Bonora S; Rusconi S; Calcagno A; Bracchi M; Viganò O; Cusato J; Lanzafame M; Trentalange A; Marinaro L; Siccardi M; D'Avolio A; Galli M; Di Perri G
    J Antimicrob Chemother; 2015 Nov; 70(11):3096-9. PubMed ID: 26174719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.
    Schipani A; Siccardi M; D'Avolio A; Baietto L; Simiele M; Bonora S; Rodríguez Novoa S; Cuenca L; Soriano V; Chierakul N; Saguenwong N; Chuchuttaworn C; Hoskins JM; Dvorak AM; McLeod HL; Davies G; Khoo S; Back DJ; Di Perri G; Owen A
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5242-50. PubMed ID: 20921307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.
    Focà E; Calcagno A; Bonito A; Simiele M; Domenighini E; D'Avolio A; Quiros Roldan E; Trentini L; Casari S; Di Perri G; Castelli F; Bonora S
    J Antimicrob Chemother; 2017 Nov; 72(11):3163-3166. PubMed ID: 28961777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
    Kile DA; MaWhinney S; Aquilante CL; Rower JE; Castillo-Mancilla JR; Anderson PL
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1227-34. PubMed ID: 22394315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
    Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
    AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
    Tian L; Liu H; Xie S; Jiang J; Han L; Huang Y; Li Y
    Clin Ther; 2011 May; 33(5):655-63. PubMed ID: 21665049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study.
    Nishijima T; Tsuchiya K; Tanaka N; Joya A; Hamada Y; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
    J Antimicrob Chemother; 2014 Dec; 69(12):3320-8. PubMed ID: 25151207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.
    Siccardi M; D'Avolio A; Baietto L; Gibbons S; Sciandra M; Colucci D; Bonora S; Khoo S; Back DJ; Di Perri G; Owen A
    Clin Infect Dis; 2008 Nov; 47(9):1222-5. PubMed ID: 18831695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.
    Calcagno A; Baietto L; Pagani N; Simiele M; Audagnotto S; D'Avolio A; De Rosa FG; Di Perri G; Bonora S
    Pharmacogenomics; 2014 Jul; 15(10):1281-6. PubMed ID: 25155930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
    Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
    Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low atazanavir concentrations in cerebrospinal fluid.
    Best BM; Letendre SL; Brigid E; Clifford DB; Collier AC; Gelman BB; McArthur JC; McCutchan JA; Simpson DM; Ellis R; Capparelli EV; Grant I;
    AIDS; 2009 Jan; 23(1):83-7. PubMed ID: 19050389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
    Boffito M; Jackson A; Amara A; Back D; Khoo S; Higgs C; Seymour N; Gazzard B; Moyle G
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4218-23. PubMed ID: 21709075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.